Vol. 24 No. 3 (2026): Blood Transfusion 3-2026 (May-June)
Full Issue
pdf
Original article
-
Multicenter evaluation of soluble CD38: neutralizing anti-CD38 pan-reactivity to enable alloantibody detection: CD38 pretreatment: a key to alloantibody detection
-
ICU-acquired infections and thrombo-embolic events in critically ill patients receiving platelet transfusion: a prospective multicenter observational study: Infections and thrombosis after PT in ICU
-
Impact of 1- and 2-unit red blood cell transfusions on continuously monitored vital signs: a longitudinal study: Transfusion and continuous vital signs
-
Exposure of red blood cell concentrates to temperatures below 0°C for a short period does not alter in vitro quality: Red cell concentrates below 0°C
-
Evaluation of stored whole blood cellular components treated with bactericidal peptides at a higher concentration than required to assess the peptide compatibility with product quality: Whole blood evaluation for compatibility with bactericidal peptides
-
Therapeutic plasma exchange-related complications in patients with immune-mediated thrombotic thrombocytopenic purpura: Complications of therapeutic plasma-exchange
Announcements
Winter Closure
The Editorial Office will be closed from December 31 to January 7, 2026.
Season’s greetings to all our readers, authors, and reviewers.
Read moreSIMTI 2026
46° Convegno Nazionale di Studi di Medicina Trasfusionale - Abstract Book (in Italian)
Read moreSETS 2026
35° Congreso de la Sociedad Española de Transfusión Sanguínea y Terapia Celular - SETS - Abstract Book (in Spanish), is online (https://www.bloodtransfusion.it/bt/issue/view/81).Madrid, 4-6 June 2026.
Read moreEditorial Office Closure Notice
Please note that the BT Editorial Office will be closed until August 26, 2026.
During this period, responses to inquiries and the processing of manuscripts may be delayed. All editorial activities will resume as usual after this date.
Thank you for your understanding.
Best regards,
BT Editorial Office
Read more
Impact Factor 2025
We are pleased to announce that Blood Transfusion has achieved a 2025 Impact Factor of 2.7.
Read more
